Uncategorized
December 21, 2005
Share
Tweet
Share

Shingles Vaccine

“Merck & Co Inc. filed a Biologics License Application (BLA) with the FDA on April 25 for ZOSTAVAX to reduce the risk of shingles and postherpetic neuralgia, the persistent, often debilitating long-term nerve pain that is the most common complication of shingles; and to reduce the total burden of pain and discomfort caused by shingles”, Merck stated in a press release.

DrTony

Prev

December 21, 2005 Kevin 14
…
Next

There goes the neighborhood

December 21, 2005 Kevin 3
…

More in Uncategorized

Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

CME Spotlights